The Lancet Oncology in conversation with

Shankar Siva on radiotherapy for primary renal cell carcinoma

November 28, 2022 The Lancet Oncology

Shankar Siva (Peter MacCallum Cancer Centre, Melbourne, Australia) discusses his Article on 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma.

Read the full article:
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma

Tell us what you thought about this episode

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv